Zobrazeno 1 - 10
of 30
pro vyhledávání: '"I. V. Kononenko"'
Autor:
N. V. Rusyaeva, I. V. Kononenko, O. K. Vikulova, M. A. Isakov, M. V. Shestakova, N. G. Mokrysheva
Publikováno v:
Сахарный диабет, Vol 27, Iss 4, Pp 321-335 (2024)
BACKGROUND: Molecular genetic testing (MGT) is increasingly accessible, improving diagnosis of monogenic diabetes (DM), particularly maturity-onset diabetes of the young (MODY). While most MODY research focuses on pediatric populations, diagnosis is
Externí odkaz:
https://doaj.org/article/d90fb4c7825c4c739a8a235ebe00e667
Publikováno v:
Сахарный диабет, Vol 26, Iss 5, Pp 473-483 (2023)
The course of difficult-to-classify types of diabetes mellitus (DM) (slowly developing immune-mediated DM of adults (LADA), monogenic forms of DM (MODY)) has common features with both type 1 DM (T1DM) and type 2 DM (T2DM), so often remain misdiagnose
Externí odkaz:
https://doaj.org/article/569c53f19d38421db50b5eb4d8f4d598
Publikováno v:
Сахарный диабет, Vol 26, Iss 3, Pp 262-274 (2023)
Latent autoimmune diabetes in adults (LADA) according to various sources is from 4 to 12% of all cases of type 2 diabetes mellitus (T2DM). Its uniqueness lies in the simultaneous combination of autoantibodies to β-cells (characteristic of T1DM) and
Externí odkaz:
https://doaj.org/article/4bac56f834ef49a7bafb6b51bf505ea5
Autor:
I. V. Kononenko, M. V. Shestakova, A. R. Elfimova, I. A. Khomyakova, A. P. Buzhilova, N. G. Mokrysheva
Publikováno v:
Сахарный диабет, Vol 25, Iss 5, Pp 418-438 (2022)
BACKGROUND: Russia is one of the most multinational states in the world. Identification of ethnic groups with a higher risk of developing DM2, analysis of risk factors for the development of DM2 will allow developing personalized approaches to the pr
Externí odkaz:
https://doaj.org/article/a8773ecb8e2c46a6a09431f8fff38a19
Autor:
M. V. Shestakova, A. Yu. Mayorov, E. V. Surkova, G. R. Galstyan, A. S. Ametov, M. B. Antsiferov, E. G. Starostina, O. G. Melnikova, L. I. Ibragimova, E. A. Andrianova, E. V. Ershova, I. A. Karpova, I. V. Kononenko, A. V. Tiselko, V. K. Fedyaeva
Publikováno v:
Сахарный диабет, Vol 25, Iss 3, Pp 299-304 (2022)
According to the decision of the WHO, therapeutic education (TE) of patients is an independent branch of medicine and an essential component of the treatment of chronic diseases, primarily diabetes mellitus and obesity. TE is implemented through the
Externí odkaz:
https://doaj.org/article/830287ca80f84a2cbd1f061cfd3019ef
Autor:
I. V. Kononenko, O. M. Smirnova
Publikováno v:
Сахарный диабет, Vol 24, Iss 4, Pp 350-356 (2021)
Sulfonylureas are widely prescribed all over the world, mainly because of their high effectiveness. At the same time, the heterogeneity of the group is obvious, primarily in relation to the effect of drugs on the risk of developing hypoglycemic event
Externí odkaz:
https://doaj.org/article/1cedd6659ae54643b631cefee6a10323
Publikováno v:
Сахарный диабет, Vol 23, Iss 6, Pp 504-513 (2021)
BACKGROUND: Less than a year has passed since the start of the new coronavirus infection COVID-19 pandemic caused by SARS-CoV-2. First published research results demonstrate a frequent increase in glycemia in patients without previously diagnosed car
Externí odkaz:
https://doaj.org/article/9fa1fc68888c48ba85e0fc96457edc11
Publikováno v:
Онкогематология, Vol 15, Iss 4, Pp 91-102 (2020)
Background. Modern standards for the treatment of both solid tumors and tumors of the blood system provide a mandatory assessment of the objective status of the patient. One of the important criteria of which is nutritional status. Underestimating th
Externí odkaz:
https://doaj.org/article/8b13b89691da4f31a94d53d0f1e59152
Publikováno v:
Сахарный диабет, Vol 23, Iss 3, Pp 229-234 (2020)
Progressive decrease in the weight and functional reserve of β-cells is one of the main pathogenetic mechanisms of development of type 2 diabetes mellitus (DM2). The rate of progression of these processes is strictly individual, which largely determ
Externí odkaz:
https://doaj.org/article/62260d1579e642eebf8122da7935c08c
Autor:
I. V. Kononenko, O. M. Smirnova
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 160-165 (2018)
Insulin glargine, synthesized using recombinant DNA technology in a concentration of 100 U/ml, was the first once-daily longacting insulin analogue introduced into clinical practice in 2000. Glargin has a well-established record of efficacy and safet
Externí odkaz:
https://doaj.org/article/472ca0256956498cae1dfb379381c112